Business Context and Reporting Period
This Form 8-K Current Report was filed by Standard BioTools Inc. (Nasdaq: LAB) on May 21, 2026. The filing discloses the Board of Directors' approval of two executive compensation plans: the 2026 Change of Control and Severance Plan and the amended 2023 Change of Control and Severance Plan. These plans govern severance benefits for the executive leadership team in the event of qualifying terminations or a change in control.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of executive compensation arrangements.
Material Changes and Plan Details
The Board approved two distinct severance frameworks effective May 21, 2026:
- 2026 Severance Plan: Applies to the Chief Financial Officer (Alex Kim) and Chief Business Officer (Sean Mackay). It supersedes prior agreements for these individuals.
- Termination outside Change of Control: 12 months of base salary, pro-rated bonus, 12 months of health coverage, and 100% equity vesting acceleration (if terminated on or before August 27, 2026).
- Termination within Change of Control: Lump-sum payment of 150% of (base salary + target bonus/average bonus), 18 months of health coverage, and 100% equity vesting acceleration.
- 2023 Severance Plan (Amended): Applies exclusively to the Chief Executive Officer, Michael Egholm, Ph.D.
- Termination outside Change of Control: 24 months of base salary (200%), 12 months of health coverage, and outplacement services.
- Termination within Change of Control: Lump-sum payment of 250% of (base salary + target bonus/average bonus), 30 months of health coverage, and 100% equity vesting acceleration.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, revenue outlook, or management commentary regarding business operations. The primary risk disclosed relates to the potential financial liability of the Company should a Change of Control occur or if executives are terminated without Cause, triggering significant cash severance payments and equity acceleration.
Investor Verification Checklist
- Verify the specific base salaries and target bonus percentages for Michael Egholm, Alex Kim, and Sean Mackay to calculate potential severance liabilities.
- Review the full text of Exhibits 10.1 through 10.5 for definitions of "Cause," "Good Reason," and "Change of Control."
- Confirm the current status of unvested equity awards held by the named executives to assess the impact of the 100% vesting acceleration clauses.
- Check for any subsequent filings regarding the actual execution of these plans or changes in executive leadership.